The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY
touchEXPERT OPINIONS for touchENDOCRINOLOGY
Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).
The experts
Dr Sue Pedersen, University of Calgary, Calgary, Canada
Prof. Carel le Roux, University College Dublin, Dublin, Ireland
Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.